Advertisement
COLL vs TEVA
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is COLL is a Hold and TEVA is a Hold.
COLL in -1.46% downward trend, falling for three consecutive days on November 02, 2026
Moving lower for three straight days is viewed as a bearish sign. Keep an eye on this stock for future declines. Considering data from situations where COLL declined for three days, in 194 of 281 cases, the price declined further within the following month. The odds of a continued downward trend are 69%.
Technical Analysis (Indicators)
Bearish Trend Analysis
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 39 of 59 cases where COLL's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 66%.
COLL broke above its upper Bollinger Band on October 15, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Bullish Trend Analysis
The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where COLL's RSI Oscillator exited the oversold zone, 17 of 24 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 71%.
The Momentum Indicator moved above the 0 level on October 14, 2026. You may want to consider a long position or call options on COLL as a result. In 64 of 95 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 67%.
COLL moved above its 50-day moving average on October 29, 2026 date and that indicates a change from a downward trend to an upward trend.
The 10-day moving average for COLL crossed bullishly above the 50-day moving average on November 02, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 9 of 12 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 75%.
Following a +4.48% 3-day Advance, the price is estimated to grow further. Considering data from situations where COLL advanced for three days, in 220 of 315 cases, the price rose further within the following month. The odds of a continued upward trend are 70%.
The Aroon Indicator entered an Uptrend today. In 174 of 230 cases where COLL Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 76%.
Fundamental Analysis (Ratings)
The Tickeron SMR rating for this company is 50 (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Valuation Rating of 58 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.471) is normal, around the industry mean (7.659). P/E Ratio (15.675) is within average values for comparable stocks, (0.330). Projected Growth (PEG Ratio) (0.664) is also within normal values, averaging (2.202). Dividend Yield (0.000) settles around the average of (0.062) among similar stocks. P/S Ratio (0.995) is also within normal values, averaging (181.047).
The Tickeron Price Growth Rating for this company is 64 (best 1 - 100 worst), indicating fairly steady price growth. COLL’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Seasonality Score of 85 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Profit vs. Risk Rating rating for this company is 90 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. COLL’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 84, placing this stock worse than average.
The Tickeron PE Growth Rating for this company is 91 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
TEVA in -2.98% downward trend, falling for three consecutive days on October 23, 2026
Moving lower for three straight days is viewed as a bearish sign. Keep an eye on this stock for future declines. Considering data from situations where TEVA declined for three days, in 203 of 305 cases, the price declined further within the following month. The odds of a continued downward trend are 67%.
Technical Analysis (Indicators)
Bearish Trend Analysis
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 34 of 60 cases where TEVA's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 57%.
TEVA broke above its upper Bollinger Band on October 09, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on November 03, 2026. You may want to consider a long position or call options on TEVA as a result. In 62 of 78 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 79%.
The Moving Average Convergence Divergence (MACD) for TEVA just turned positive on November 03, 2026. Looking at past instances where TEVA's MACD turned positive, the stock continued to rise in 34 of 40 cases over the following month. The odds of a continued upward trend are 85%.
Following a +5.30% 3-day Advance, the price is estimated to grow further. Considering data from situations where TEVA advanced for three days, in 227 of 298 cases, the price rose further within the following month. The odds of a continued upward trend are 76%.
The Aroon Indicator entered an Uptrend today. In 227 of 282 cases where TEVA Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 80%.
Fundamental Analysis (Ratings)
The Tickeron Profit vs. Risk Rating rating for this company is 6 (best 1 - 100 worst), indicating low risk on high returns. The average Profit vs. Risk Rating rating for the industry is 84, placing this stock better than average.
The Tickeron PE Growth Rating for this company is 7 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 37 (best 1 - 100 worst), indicating steady price growth. TEVA’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 72 (best 1 - 100 worst), indicating slightly better than average sales and a considerably profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Valuation Rating of 77 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (6.296) is normal, around the industry mean (7.659). P/E Ratio (67.500) is within average values for comparable stocks, (0.330). Projected Growth (PEG Ratio) (0.980) is also within normal values, averaging (2.202). Dividend Yield (0.008) settles around the average of (0.062) among similar stocks. P/S Ratio (2.589) is also within normal values, averaging (181.047).
COLL | TEVA | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 25 | 88 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 58 Fair valued | 77 Overvalued | |
PROFIT vs RISK RATING 1..100 | 90 | 6 | |
SMR RATING 1..100 | 50 | 72 | |
PRICE GROWTH RATING 1..100 | 64 | 37 | |
P/E GROWTH RATING 1..100 | 91 | 7 | |
SEASONALITY SCORE 1..100 | 85 | n/a |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
COLL's Valuation (58) in the Pharmaceuticals Other industry is in the same range as TEVA (77) in the Pharmaceuticals Generic industry. This means that COLL’s stock grew similarly to TEVA’s over the last 12 months.
TEVA's Profit vs Risk Rating (6) in the Pharmaceuticals Generic industry is significantly better than the same rating for COLL (90) in the Pharmaceuticals Other industry. This means that TEVA’s stock grew significantly faster than COLL’s over the last 12 months.
COLL's SMR Rating (50) in the Pharmaceuticals Other industry is in the same range as TEVA (72) in the Pharmaceuticals Generic industry. This means that COLL’s stock grew similarly to TEVA’s over the last 12 months.
TEVA's Price Growth Rating (37) in the Pharmaceuticals Generic industry is in the same range as COLL (64) in the Pharmaceuticals Other industry. This means that TEVA’s stock grew similarly to COLL’s over the last 12 months.
TEVA's P/E Growth Rating (7) in the Pharmaceuticals Generic industry is significantly better than the same rating for COLL (91) in the Pharmaceuticals Other industry. This means that TEVA’s stock grew significantly faster than COLL’s over the last 12 months.
| COLL | TEVA | |
|---|---|---|
| RSI ODDS (%) | 2 days ago 71% | N/A |
| Stochastic ODDS (%) | 2 days ago 66% | 2 days ago 57% |
| Momentum ODDS (%) | 2 days ago 67% | 2 days ago 79% |
| MACD ODDS (%) | N/A | 2 days ago 85% |
| TrendWeek ODDS (%) | 2 days ago 70% | 2 days ago 76% |
| TrendMonth ODDS (%) | 2 days ago 71% | 2 days ago 73% |
| Advances ODDS (%) | 8 days ago 70% | 7 days ago 76% |
| Declines ODDS (%) | 4 days ago 69% | 14 days ago 67% |
| BollingerBands ODDS (%) | 2 days ago 61% | 2 days ago 58% |
| Aroon ODDS (%) | 2 days ago 76% | 2 days ago 80% |
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
COLL’s FA Score shows that 0 FA rating(s) are green while TEVA’s FA Score has 2 green FA rating(s).
- COLL’s FA Score: 0 green, 5 red.
- TEVA’s FA Score: 2 green, 3 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
COLL’s TA Score shows that 6 TA indicator(s) are bullish while TEVA’s TA Score has 4 bullish TA indicator(s).
- COLL’s TA Score: 6 bullish, 3 bearish.
- TEVA’s TA Score: 4 bullish, 3 bearish.
Price Growth
COLL (@Pharmaceuticals: Generic) experienced а +1.89% price change this week, while TEVA (@Pharmaceuticals: Generic) price change was +4.70% for the same time period.
The average weekly price growth across all stocks in the @Pharmaceuticals: Generic industry was +4.74%. For the same industry, the average monthly price growth was +2.25%, and the average quarterly price growth was +25.89%.
Reported Earning Dates
COLL is expected to report earnings on Nov 05, 2026.
TEVA is expected to report earnings on Feb 10, 2027.
Industries' Descriptions
@Pharmaceuticals: Generic (+4.74% weekly)A generic drug contains the same chemical substance as a drug that was originally protected by patents. Generic drugs are generally sold at cheaper price points, compared to name-brand pharmaceuticals, after patents for the more expensive drugs lapse. The generic drug industry has created a major market, thanks to the lower pricing. According to the Center for Justice and Democracy at New York Law School, 80 percent of all drugs prescribed are generic, and generic drugs are chosen 94 percent of the time when they are available. But their manufacturers must be able to prove to the FDA that they can be effective substitutes for the original drugs. Some of the major generic drug makers include Zoetis, Inc., Allergan plc and Mylan N.V.
Advertisement
TEVA and
Correlation & Price change
A.I.dvisor indicates that over the last year, TEVA has been loosely correlated with AMRX. These tickers have moved in lockstep 39% of the time. This A.I.-generated data suggests there is some statistical probability that if TEVA jumps, then AMRX could also see price increases.
| Ticker / NAME | Correlation To TEVA | 1D Price Change % | ||
|---|---|---|---|---|
| TEVA | 100% | -0.14% | ||
| AMRX - TEVA | 39% Loosely correlated | -1.29% | ||
| VTRS - TEVA | 34% Loosely correlated | +1.59% | ||
| COLL - TEVA | 28% Poorly correlated | -0.25% | ||
| HROW - TEVA | 26% Poorly correlated | +0.74% | ||
| SNDL - TEVA | 26% Poorly correlated | +4.44% | ||
More | ||||